- Home
- EWTX vs CERT Comparison
EWTX vs CERT Comparison
Compare EWTX & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- CERT
- Stock Information
- Founded
- EWTX 2017
- CERT 2008
- Country
- EWTX United States
- CERT United States
- Employees
- EWTX N/A
- CERT N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- CERT Retail: Computer Software & Peripheral Equipment
- Sector
- EWTX Health Care
- CERT Technology
- Exchange
- EWTX Nasdaq
- CERT Nasdaq
- Market Cap
- EWTX 1.6B
- CERT 1.9B
- IPO Year
- EWTX 2021
- CERT 2020
- Fundamental
- Price
- EWTX $15.40
- CERT $12.27
- Analyst Decision
- EWTX Buy
- CERT Buy
- Analyst Count
- EWTX 10
- CERT 8
- Target Price
- EWTX $37.90
- CERT $15.57
- AVG Volume (30 Days)
- EWTX 875.0K
- CERT 1.8M
- Earning Date
- EWTX 11-06-2025
- CERT 11-06-2025
- Dividend Yield
- EWTX N/A
- CERT N/A
- EPS Growth
- EWTX N/A
- CERT N/A
- EPS
- EWTX N/A
- CERT 0.05
- Revenue
- EWTX N/A
- CERT $405,755,000.00
- Revenue This Year
- EWTX N/A
- CERT $11.70
- Revenue Next Year
- EWTX N/A
- CERT $8.05
- P/E Ratio
- EWTX N/A
- CERT $247.31
- Revenue Growth
- EWTX N/A
- CERT 11.61
- 52 Week Low
- EWTX $10.60
- CERT $8.64
- 52 Week High
- EWTX $38.12
- CERT $15.69
- Technical
- Relative Strength Index (RSI)
- EWTX 51.61
- CERT 51.57
- Support Level
- EWTX $14.88
- CERT $11.64
- Resistance Level
- EWTX $16.08
- CERT $12.85
- Average True Range (ATR)
- EWTX 0.85
- CERT 0.63
- MACD
- EWTX -0.04
- CERT -0.11
- Stochastic Oscillator
- EWTX 50.88
- CERT 27.96
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.